News
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022.
In connection with the earnings release
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes
DGAP-News: Abivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca
Pfizer Declares Second-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common
Pfizer Declares Second-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common
Novocure Reports First Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology
ICON Reports First Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the first quarter ended March 31, 2022.
CEO Dr. Steve
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant)
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant)
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On April 22
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate
Poxel Announces Its Participation in Upcoming Scientific Conferences
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement of $26.5 million with Silicon
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
-
Bank of America Securities
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire